Led · Series A · Jan 2022

Engitix leverages one of the largest proprietary datasets of high-resolution extracellular matrix (ECM) profiles across cancer and fibrotic diseases to discover and develop new drugs. By decoding disease-specific ECM signatures, the company designs therapeutics intended to act directly within diseased tissue microenvironments. Its preclinical pipeline includes multiple oncology and fibrosis programs that it plans to progress toward the clinic using the newly secured capital. Engitix’s strategy sits at the intersection of data science, biology and drug development, aiming to deliver differentiated ECM-targeted medicines that improve patient outcomes. Current external relationships include a drug-discovery partnership with Dompé farmaceutici and development collaborations with Takeda focused on advanced fibrotic liver diseases. The firm states that the additional funds will accelerate its platform expansion and pipeline advancement. No revenue or user metrics were disclosed in the article.

Led · Equity · Jul 2011

Advanced Accelerator Applications is a molecular nuclear medicine (MNM) company that develops and commercializes diagnostic and therapeutic products, including PET and SPECT solutions. The company focuses on molecular imaging and personalized medicines, particularly for treatment of diseases such as cancer. It operates 17 production and R&D facilities across Europe, Israel and North America and has over 270 employees in 10 countries (France, Italy, Germany, Switzerland, Spain, Poland, Portugal, Israel, U.S., Canada). Founded in 2002 and led by CEO Stefano Buono, the company plans to use the new funding for expansion and clinical trials of its MNM portfolio. Financially, Advanced Accelerator Applications expected 2013 revenues of €56.6m (a 27% increase versus 2012) and an EBITDA of €14m (a 49% increase versus 2012). Advanced Accelerator Applications (AAA) develops and commercializes diagnostic and therapeutic applications, with a research focus on molecular imaging and personalized medicines. The company produces PET and SPECT products and pursues radio metabolic therapies and diagnostic agents. AAA intends to use new funds to advance clinical trials across its portfolio, including Lutathera® for diagnosis and treatment of Gastro-Entero-Pancreatic Neuro Endocrine Tumours (GEPNETs). It has invested prior proceeds into construction of laboratories and R&D activities. To date the company has raised more than €74m to finance its facilities and research. AAA was founded in 2002 as a spin-off from CERN and is led by CEO Stefano Buono, operating 11 production and R&D facilities in France, Italy, Switzerland, Spain and the USA.